CPT2下调使肝细胞癌适应富含脂质环境并通过肥胖中酰基肉碱蓄积促进癌变
该研究对二乙基亚硝胺注射后喂养正常或高脂饮食小鼠的non-tumour与HCC组织行代谢组学分析,发现HFD小鼠HCC组织及血清中酰基肉碱蓄积,NASH-HCC患者血清同样升高,与CPT2下调相关;CPT2下调抑制脂肪酸β氧化,使HCC细胞抵抗脂毒性并促进癌变。
要点
- 高脂饮食小鼠HCC组织及血清中酰基肉碱蓄积,NASH-HCC患者血清亦升高。
- CPT2下调见于人SH-HCC,其介导脂肪酸β氧化抑制,解释HCC脂肪变性。
- HFD喂养联合肉碱补充在体内协同增强HCC发生并伴酰基肉碱蓄积。
核心结论
- 在肥胖驱动和NASH驱动的HCC中,CPT2下调介导的代谢重编程使HCC细胞逃避脂毒性并促进肝癌发生。
研究设计与样本
- 对二乙基亚硝胺注射后喂养正常饮食或高脂饮食(HFD)小鼠的non-tumour与HCC组织行综合代谢组学分析,并评估肥胖介导的代谢改变在肝癌发生中的意义。
主要发现
- HFD喂养小鼠的HCC组织及血清中可见酰基肉碱类物质广泛蓄积,NASH-HCC患者血清中亦见类似升高。
- 酰基肉碱蓄积可归因于肉碱棕榈酰转移酶2(CPT2)下调,人SH-HCC中亦可见CPT2下调。
- CPT2下调诱导脂肪酸β氧化抑制,可解释HCC的脂肪变性改变。
- HCC细胞中CPT2敲低通过抑制Src介导的JNK活化使其抵抗脂毒性。
- 油酰肉碱通过STAT3活化增强HCC细胞成球能力,提示酰基肉碱蓄积是CPT2下调的替代标志物并直接参与肝癌发生。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Metabolic reprogramming of tumour cells that allows for adaptation to their local environment is a hallmark of cancer. Interestingly, obesity-driven and non-alcoholic steatohepatitis (NASH)-driven hepatocellular carcinoma (HCC) mouse models commonly exhibit strong steatosis in tumour cells as seen in human steatohepatitic HCC (SH-HCC), which may reflect a characteristic metabolic alteration. DESIGN: Non-tumour and HCC tissues obtained from diethylnitrosamine-injected mice fed either a normal or a high-fat diet (HFD) were subjected to comprehensive metabolome analysis, and the significance of obesity-mediated metabolic alteration in hepatocarcinogenesis was evaluated. RESULTS: The extensive accumulation of acylcarnitine species was seen in HCC tissues and in the serum of HFD-fed mice. A similar increase was found in the serum of patients with NASH-HCC. The accumulation of acylcarnitine could be attributed to the downregulation of carnitine palmitoyltransferase 2 (CPT2), which was also seen in human SH-HCC. CPT2 downregulation induced the suppression of fatty acid β-oxidation, which would account for the steatotic changes in HCC. CPT2 knockdown in HCC cells resulted in their resistance to lipotoxicity by inhibiting the Src-mediated JNK activation. Additionally, oleoylcarnitine enhanced sphere formation by HCC cells via STAT3 activation, suggesting that acylcarnitine accumulation was a surrogate marker of CPT2 downregulation and directly contributed to hepatocarcinogenesis. HFD feeding and carnitine supplementation synergistically enhanced HCC development accompanied by acylcarnitine accumulation in vivo. CONCLUSION: In obesity-driven and NASH-driven HCC, metabolic reprogramming mediated by the downregulation of CPT2 enables HCC cells to escape lipotoxicity and promotes hepatocarcinogenesis.
引用
- Fujiwara N, Nakagawa H, Enooku K, et al. CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity. Gut. 2018. PMID: 29437870. doi:10.1136/gutjnl-2017-315193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。